38 results on '"Christen, Thomas"'
Search Results
2. Self-organized giant magnetic structures via additive manufacturing in NdFeB permanent magnets
3. Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation.
4. Intracardiac Echocardiography to Guide Watchman FLX Implantation: The ICE LAA Study.
5. Simulation of unipolar space charge controlled electric fields
6. Optimizing energy storage devices using Ragone plots
7. PO-03-134 LONG TERM OUTCOMES FOLLOWING LAAO IN A LARGE MEDICARE POPULATION.
8. CE-452771-4 OUTCOMES WITH DIFFERENT POSTPROCEDURAL ANTITHROMBOTIC THERAPY REGIMENS FOLLOWING LEFT ATRIAL APPENDAGE OCCLUSION.
9. CE-452771-3 LEFT ATRIAL APPENDAGE OCCLUSION WITH THE WATCHMAN FLX AND CONCOMITANT CATHETER ABLATION PROCEDURES.
10. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
11. Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium.
12. B-PO01-044 REAL WORLD OUTCOMES WITH WATCHMAN: 2-YEAR RESULTS FROM THE NESTED POST APPROVAL STUDY.
13. Electron and hole mobility edges in polyethylene from material simulations.
14. PO-656-04 SAFETY AND EFFECTIVENESS OF SAME DAY DISCHARGE AFTER LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN FLX.
15. Increased Glucose Uptake in Visceral Versus Subcutaneous Adipose Tissue Revealed by PET Imaging.
16. Minimum entropy production closure of the photo-hydrodynamic equations for radiative heat transfer
17. Do allelic variants of the connexin37 1019 gene polymorphism differentially predict for coronary artery disease and myocardial infarction?
18. B-PO01-078 REAL-WORLD CLINICAL OUTCOMES WITH A NEXT-GENERATION LEFT ATRIAL APPENDAGE CLOSURE DEVICE: FIRST REPORT FROM THE FLXIBILITY POST-APPROVAL STUDY.
19. Anticoagulation Alone vs Anticoagulation Plus Aspirin or DAPT Following Left Atrial Appendage Occlusion.
20. Advantages of short repetition time resting-state functional MRI enabled by simultaneous multi-slice imaging.
21. Corrigendum to “Electron and hole mobility edges in polyethylene from material simulations” [Chem. Phys. Lett. 613 (2014) 15–18].
22. Connexin37 protects against atherosclerosis by controlling monocyte recruitment
23. Synchrotron microbeam radiation therapy induces hypoxia in intracerebral gliosarcoma but not in the normal brain.
24. TCT-33 Racial Disparities in the Utilization and Outcomes of LAA Occlusion Using Watchman FLX: A SURPASS analysis of the NCDR LAAO Registry.
25. One-Year Outcomes in "Real-World" Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS]).
26. Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography.
27. Hypoxia But Not Inflammation Augments Glucose Uptake in Human Macrophages: Implications for Imaging Atherosclerosis With 18Fluorine-Labeled 2-Deoxy-D-Glucose Positron Emission Tomography
28. Multicomponent permanent magnets for enhanced electrical device efficiency.
29. A FIRST-IN-HUMAN STUDY OF THE SECOND-GENERATION, THIN-STRUT, EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLD: 6-MONTH IVUS AND OCT RESULTS FROM THE FAST CLINICAL TRIAL.
30. TCT-583 Final 5-Year Results in Unselected Patients Implanted With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent: The PROMUS Element Plus US Post-Approval Study.
31. CLINICAL OUTCOMES TO 4 YEARS IN PATIENTS IMPLANTED WITH BIOABSORBABLE POLYMER SYNERGY VERSUS PERMANENT POLYMER EVEROLIMUS-ELUTING STENTS: THE EVOLVE II RANDOMIZED TRIAL.
32. TCT-729 Four-Year Clinical Outcomes in ‘Real-World’ Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent: Results from the PROMUS Element Plus US Post-Approval Study (PE-Plus PAS).
33. TCT-846 Clinical Outcomes in Patients Treated With the Fully Absorbable, Everolimus-Eluting RENUVIATM Scaffold: Primary Endpoint Results from the FAST First Human Use Study.
34. THREE-YEAR RESULTS FROM THE EVOLVE II RANDOMIZED TRIAL: LATE CLINICAL OUTCOMES WITH BIORESORBABLE COMPARED TO PERMANENT POLYMER EVEROLIMUS-ELUTING.
35. THREE-YEAR OUTCOMES IN ‘REAL-WORLD’ PATIENTS TREATED WITH A THIN-STRUT, PLATINUM-CHROMIUM, EVEROLIMUS-ELUTING STENT IN THE PROMUS ELEMENT PLUS U.S. POST-APPROVAL STUDY (PE-PLUS PAS).
36. LATE CLINICAL OUTCOMES AFTER BIORESORBABLE OR PERMANENT POLYMER EVEROLIMUS-ELUTING STENTS: 2-YEAR RESULTS FROM THE EVOLVE II RANDOMIZED TRIAL.
37. Primary Endpoint Results of the TAXUS Libertē Post-Approval Study.
38. TAXUS Liberté paclitaxel-eluting stent with aspirin plus prasugrel is associated with low target vessel failure, bleeding and adverse event rates among diabetic patients with “on-label” stent indications.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.